Get the Stockscreener App
1.275
10.87%
0.125
Allarity Therapeutics Inc stock is traded at $1.275, with a volume of 188.69K.
It is up +10.87% in the last 24 hours and up +0.39% over the past month.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
See More
Previous Close:
$1.15
Open:
$1.18
24h Volume:
188.69K
Relative Volume:
1.18
Market Cap:
$20.25M
Revenue:
-
Net Income/Loss:
$-11.23M
P/E Ratio:
-1.6046
EPS:
-0.7946
Net Cash Flow:
$-14.83M
1W Performance:
+9.91%
1M Performance:
+0.39%
6M Performance:
-20.81%
1Y Performance:
+75.84%
1-Day Range:
$1.1301
$1.28
1-Week Range:
$1.1301
$1.28
52-Week Range:
$0.6585
$2.35
Allarity Therapeutics Inc Stock (ALLR) Company Profile
Name
Allarity Therapeutics Inc
Sector
Industry
Phone
401-426-4664
Address
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.2799 | 18.19M | 0 | -11.23M | -14.83M | -0.7946 |
VRTX
Vertex Pharmaceuticals Inc
|
434.80 | 113.64B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
741.55 | 81.18B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
795.71 | 49.78B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
324.00 | 42.87B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.93 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
Allarity Therapeutics Inc Stock (ALLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-25 | Initiated | Ascendiant Capital Markets | Buy |
Allarity Therapeutics Inc Stock (ALLR) Latest News
Allarity Therapeutics, Inc. (ALLR) stock price, news, quote and history - uk.finance.yahoo.com
Allarity Therapeutics Reports 2025 Financial Results, Advances Stenoparib in Ovarian and Lung Cancer with FDA Fast Track Designation - Minichart
Allarity Therapeutics posts $320k revenue, $11.2M net loss and $14.7M year-end cash (2025) - TradingView
Allarity Therapeutics (NASDAQ: ALLR) cuts 2025 loss to $11.2M and posts first revenue - Stock Titan
ALLR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Allarity Therapeutics, Inc. (ALLR) Stock Price, News, Quote & History - ca.finance.yahoo.com
TON Strategy Company (VERB) Reports FY2025 Earnings - AlphaStreet
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress - Investing News Network
Allarity Therapeutics, Inc. (ALLR) Reports FY2025 Earnings - AlphaStreet
Purple Innovation, Inc. (PRPL) Reports Q4 Earnings - AlphaStreet
Allarity Therapeutics reports full year 2025 financial results and corporate progress - marketscreener.com
Market Catalysts: Is Allarity Therapeutics Inc stock forming a cup and handleWeekly Investment Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Allarity Therapeutics Reports Full Year 2025 Financial Results And Corporate Progress - TradingView
Cancer drug gets FDA Fast Track as Allarity says cash lasts to 2028 - Stock Titan
Stenoparib push: Allarity Therapeutics (NASDAQ: ALLR) reshapes cancer pipeline - Stock Titan
Allarity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Expands By 27.2% - Defense World
Tranche Update on Allarity Therapeutics, Inc.'s Equity Buyback Plan announced on March 3, 2025. - marketscreener.com
Shorts Report: Can Allarity Therapeutics Inc disrupt its industry2026 Market Trends & Consistent Return Strategy Ideas - baoquankhu1.vn
Former Allarity Executive Winnows SEC’s FDA Approval Scheme Suit - Bloomberg Law News
Allarity Therapeutics (ALLR) Projected to Post Quarterly Earnings on Monday - Defense World
Volume Summary: Will Allarity Therapeutics Inc stock recover after earningsDip Buying & Safe Entry Trade Signal Reports - baoquankhu1.vn
Pharma News: Can Allarity Therapeutics Inc expand its profit margins2026 Bull vs Bear & Low Volatility Stock Recommendations - baoquankhu1.vn
Allarity Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | C6D | US0167441049 - marketscreener.com
Aug Spikes: Whats the analyst consensus on Allarity Therapeutics IncGlobal Markets & AI Driven Stock Reports - baoquankhu1.vn
Inflation Data: Can Allarity Therapeutics Inc disrupt its industry2026 Technicals & Technical Entry and Exit Tips - baoquankhu1.vn
MACD Signal: Can Allarity Therapeutics Inc expand its profit marginsTrade Performance Summary & Stock Market Timing Techniques - baoquankhu1.vn
Allarity’s Terminated Breast Cancer Trial Signals Setback for DRP-Guided Chemotherapy - TipRanks
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus
Big Picture: Is Allarity Therapeutics Inc backed by strong institutional buying2026 Momentum Check & Community Verified Watchlist Alerts - baoquankhu1.vn
Allarity Therapeutics Secures $20 Million Debt Financing to Advance Stenoparib Toward FDA Approval and Extend Cash Runway to 2028 - Minichart
Allarity closes $20M non-convertible debt to fund stenoparib Phase 2 and extend runway - TradingView
Allarity Therapeutics (NASDAQ: ALLR) closes $20M debt to fund trials - Stock Titan
Allarity closes $20M financing for stenoparib advancement - Yahoo Finance
Allarity secures $20M debt financing to extend cash runway By Investing.com - Investing.com South Africa
Allarity Therapeutics, Inc. announced that it has received $20.93 million in funding - marketscreener.com
Allarity Therapeutics, Inc. Closes $20 Million Non-Convertible Debt Financing - marketscreener.com
Allarity secures $20M debt financing to extend cash runway - Investing.com
Allarity Therapeutics Secures $20 Million Structured Note Financing - TipRanks
Allarity Therapeutics Secures $20.9M Notes Financing From Streeterville, With Collateral Agreements - TradingView
Allarity Therapeutics closes $20 million financing to accelerate the advance of stenoparib toward FDA approval and commercialization - marketscreener.com
Allarity Therapeutics (ALLR) enters $20.93M secured note deal with covenants - Stock Titan
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib ... - Bluefield Daily Telegraph
Allarity Therapeutics Closes $20 Million Financing To Accelerate The Advance Of Stenoparib Toward FDA Approval And Commercialization - TradingView
Allarity Therapeutics Closes $20 Million Financing to - GlobeNewswire
Aug Analyst Calls: What is Allarity Therapeutics Incs 5 year growth outlookJuly 2025 Short Interest & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Retail Trends: What are REV Group Incs earnings expectationsJuly 2025 Chart Watch & Real-Time Stock Entry Alerts - baoquankhu1.vn
ALLR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Allarity Therapeutics doses first patients in VA-funded small cell lung cancer trial - Mugglehead Investment Magazine
Why analysts upgrade Allarity Therapeutics Inc. stockRate Hike & Real-Time Buy Zone Alerts - mfd.ru
Allarity Therapeutics doses first patients in VA-funded Phase 2 SCLC trial - TradingView
Allarity Therapeutics Inc Stock (ALLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.25%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):